Akademik Veri Yönetim Sistemi
Anestezi Dergisi, cilt.25, sa.4, ss.171-180, 2017 (Scopus, TRDizin)
Pulmonary hypertension (PH) is one of the common complications of congenital heart diseases (CHD) and significantly increases morbidity and mortality during perioperative period. The diagnosis of PH and assessment of its severity in the preoperative period is crucial to avoid complications during the perioperative period and to improve the success of the surgery. The most important factor that increases the mortality and morbidity is the high risk of pulmonary hypertensive crisis in these patients. Pulmonary hypertensive crisis can be triggered by various factors related to anesthetic management; such as acute rise in pulmonary vascular resistance leading to acute right ventricular failure and severe tissue hypoxia resulting in death. The avoidance of pulmonary hypertensive crisis, and when it develops, the recognition and treatment are indispensible. During the perioperative period, particularly selective pulmonary vasodilators have been highlighted for the treatment of newly developed or worsening pulmonary hypertension. Among those, the most commonly addressed and compared agents for their effectiveness are inhaled nitrous oxide and inhaled ilioprost. Our aim is to define and summarize the currently available data pertaining to effective methods to avoid the development of pulmonary hypertension and treatment methods to treat effectively when it occurs in pediatric group patients undergoing surgery for congenital heart disease.